Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.59 |
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27788617 | 0.81 | ACP3 (0.46) | ANPEPHTR2A | |
| SCHEMBL7127466 | 0.76 | ANPEP (0.61) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL28518727 | 0.74 | ANPEP (1.00) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL2187484 | 0.74 | ANPEP (0.59) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL2278230 | 0.74 | ANPEP (0.59) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL18999729 | 0.74 | ANPEP (1.00) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL30633009 | 0.74 | ANPEP (0.59) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL6514594 | 0.74 | ANPEP (0.59) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL7742080 | 0.74 | ANPEP (0.59) | ANPEPHTR2ACYP1A2HRH1HTR2C | |
| SCHEMBL17070963 | 0.72 | ANPEP (0.57) | ANPEPHTR2ACYP1A2HRH1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | ANPEP 3558/4885HTR2A 4225/4885CYP1A2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.